HALO Stock — Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc. (HALO)

Updated October 16, 2026.

HALO is a Stock. Total return is 2835.9% over the past 22.6 years, 1909.3 points ahead of SPY at 926.6%.

Halozyme Therapeutics is a biopharmaceutical company that researches, develops, and commercializes proprietary enzymes and delivery devices based on its patented recombinant human hyaluronidase enzyme, which enables injection of biologics and other therapeutic molecules. The company does not currently have an established distribution frequency. Halozyme appeals to growth-oriented investors seeking exposure to specialty pharmaceutical and drug-delivery innovation rather than current income.

HALO performance versus SPY

Price and return data through 2026-10-16.

Total return is 2835.9% over the past 22.6 years, 1909.3 points ahead of SPY at 926.6%. Over the past year its total return — price change plus distributions reinvested — is 82.2%. Its deepest 1-year drawdown was 24.1%.

HALO key facts

Asset type

Stock

Asset class

Equity

Inception date

03/12/2004

Distribution frequency

None

Last close

$121.84 (as of 2026-10-16)

Market cap

$13,828,596,320

Average volume

2082169.0

Beta

0.877

Payout ratio

0.0%

P/E ratio

35.63

Forward P/E

11.4548

EPS

$3.42

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

HALO risks and drawbacks

The deepest 1-year drawdown on record here is 24.1%.

Who may consider HALO — and who may not

It is a weaker fit for investors who need monthly cash flow (HALO does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on HALO

• ETFs holding HALO
• All tickers starting with H

Tagged: Healthcare.

Frequently asked questions